The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 03, 2025

Filed:

Oct. 29, 2024
Applicant:

Guardant Health, Inc., Palo Alto, CA (US);

Inventor:

AmirAli Talasaz, Atherton, CA (US);

Assignee:

Guardent Health, Inc., Palo Alto, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12N 15/10 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6869 (2018.01); C12Q 1/6874 (2018.01); C12Q 1/6886 (2018.01); G16B 30/00 (2019.01); G16B 30/10 (2019.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12N 15/1065 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/6874 (2013.01); G16B 30/00 (2019.02); G16B 30/10 (2019.02); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01);
Abstract

The present disclosure provides a method for monitoring residual disease in a subject. Generally, the method comprises determining a frequency of cancer mutations from a first sample obtained from a tumor biopsy from the subject; determining a frequency of the cancer mutations discovered in the first sample from a second sample comprising cell-free deoxyribonucleic acid (cfDNA) molecules that is obtained from the subject after the subject has undergone a course of treatment for cancer; and determining a presence or absence of cancer in the subject based on an analysis of the frequency of the cancer mutations from sequence data from the second sample.


Find Patent Forward Citations

Loading…